Health
Novo Nordisk Gains as CFO Touts Wegovy’s Rebound Potential
Takeaways NEW
Novo Nordisk A/S surged on expectations that some competition for its blockbuster obesity shot Wegovy will subside, paving the way for a sales rebound later this year.
The stock rose as much as 6.9% in Copenhagen as investors looked past a trimmed financial forecast from the Danish drugmaker.